Introduction
Recent studies indicate that inflammation is a critical component of tumor progression, and is evident that the tumor microenvironment, which is orchestrated by inflammatory cells, plays a central role in immunologic response and tumor escape (1) . In the presence of inflammation, regulatory T cells (Tregs) accumulate in tumor tissue and protect cancer cells from antitumor immunity (2) ; dendritic cells (DCs) induce tolerance rather than immunity (3) ; inhibitory signals, such as engagement of programmed death-1 (PD-1) with its two ligands [programmed death ligand-1(PD-L1) and PD-L2], regulate both the effectiveness of tumor antigen cross-priming and the function of effector cells at tumor sites (4); tumor cells can express PD-L1 that inhibit T-cell activation (5, 6) . In this context, modulation of immune responses in the tumor microenvironment is a critical mechanism attributed to tumor evasion. Many studies were directed at the analyses of inhibitory signals, including the PD-L1/PD-1 pathway, in the function of immune effector cells and immune evasion by cancer cells (4) (5) (6) (7) .
PD-1 expression is induced by T-cell receptor signaling and is increased on activated CD4 and CD8 T cells (8, 9) . PD-1 activation limits the activity of T cells in the periphery during an inflammatory response (10) . The ligands for PD-1, PD-L1 (B7-H1) and PD-L2 (B7-DC) belong to the B7:CD28 family of ligands (11) . Consistent with the inhibitory role of PD-1, PD-1-deficient mice develop a severe autoimmune disease (12) (13) (14) (15) , atherosclerosis (16) , allograft vascular disease (17) and encephalomyelitis (18) . Several groups have reported that engagement of PD-1 by PD-L1 or PD-L2 results in inhibition of T-cell proliferation or altered cytokine production (12, 13, 19) .
Several lines of evidence also implicate the PD-1/PD-L1 pathway in T-cell exhaustion in cancer (20) . PD-1 expression is found on tumor-infiltrating CD8 + T cells in multiple solid tumors (21) (22) (23) , and PD-1 blockade potentiates an antitumor immune response (21) . Some human studies show that the presence of PD-L1-positive tumor cells is directly correlated with poorer prognosis and inversely correlated with CD8 + T cells infiltrating tumors (24) (25) (26) . Our group recently demonstrated that PD-1 is detected in 20-40% of T cells in human tumor samples from patients with oral squamous cell carcinoma (SCC) (27) . Although these reports have suggested a direct correlation between PD-1:PD-L1 and tumor escape, the involvement of these molecules in SCC has not been explored.
The development of SCC, one of the most common human cancers worldwide, is accompanied by a massive infiltration of mononuclear cells into the tumor, leading to local and systemic production of cytokines, chemokines and other immune mediators, including nitric oxide (28) (29) (30) . In addition, progressive alterations in cytokeratins (CKs) expression are closely associated with the development of a variety of skin cancers, including SCC (31, 32) . CK1 and CK10 are expressed in well-differentiated SCC in association with keratinization (33) (34) (35) . Notably, in poorly differentiated SCC or SCC areas, there is inappropriate expression of simple epithelial keratins CK8/CK18 and CK19, and sometimes even CK7 (33) .
Tumor-specific immune responses are normally not enough to eradicate the tumors. The paucity of immunological danger signals necessary for immune activation, the increased concentration of immunosuppressive factors, including cytokines and cells, in the tumor microenvironment indicate that immune regulation has an active role in cancer progression (36) . The identification of negative immunoreceptors on T cells, receptors that dampen the ability of T cells to proliferate, provide a novel therapeutic target that may lead to the enhanced tumor-specific T-cell immunity in vivo. To our knowledge, reports addressing the direct involvement of PD-1 in tumor progression in a model of murine SCC, which mimics the characteristics of human SCC, have not been studied. Our results showed that the immune neutralization of PD-1 + cells resulted in decreased papilloma incidence associated with CD4 + and CD8 + T cells infiltrate, higher levels of interferon-γ (IFN-γ) and decreased levels of transforming growth factor-β (TGF-β) in the tumor lesions. These findings support the role of PD-1 blockade as a promising component of immunotherapy against SCC.
Materials and methods

Mice
Female Balb/c mice that were 6-8 weeks old were purchased from the Bauru School of Dentistry, University of São Paulo. Each mouse was housed in an Abbreviations: Ab, antibody; CK, cytokeratin; DC, dendritic cell; DMBA, 7,12-Dimethylbenz[a]anthracene; IFN-γ, interferon-γ; IgG, immunoglobulin G; LN, lymph node; PCNA, proliferating cell nuclear antigen; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PMA, phorbol 12-myristate 13-acetate; SCC, squamous cell carcinoma; TGF-β, transforming growth factor-β.
PD-1 in the squamous cell carcinoma isolated cage. Food and water were provided ad libitum. The mice were maintained on a 12 h light/12 h dark photocycle in a controlled temperature environment and were quarantined for a minimum of 1 week before the beginning of any treatment. Groups of mice were randomly killed in 2 week intervals until a 16 −4 M solution in acetone) (Sigma-Aldrich) for 16 weeks as described previously (37) . The tumor incidence was recorded every other week through visual inspection. Papillomas were characterized by folded epidermal hyperplasia protruding from the skin surface, and carcinomas were usually endophytic tumors presenting as plaques with an ulcerated surface. Care of experimental animals was in accordance with institutional guidelines. Survival rates were determined in independent groups of animals. Tumors were collected 16 weeks after initiation and were processed as described below.
Antibodies and treatment
The blockage of PD-1 was performed by intraperitoneal injection of 500 μg/ ml hamster anti-mouse PD-1 (J43) (BD Biosciences) in the fourth and eighth weeks after the first DMBA application. Controls received 500 μg/ml of normal hamster immunoglobulin G (IgG) diluted in phosphate-buffered saline.
Isolation of leukocytes
To characterize the leukocytes present in the tumor site, biopsies of skin lesions from mice were collected and incubated for 40 min at 37°C in RPMI 1640 medium containing 50 μg/ml of a collagenase CI enzyme blend (Boehringer Ingelheim Chemicals, Petersburg, VA), as described previously (38) . The tissues were subsequently dissociated for 4 min in the presence of RPMI 1640 with 10% serum and 0.05% DNase (Sigma-Aldrich) using a Medimachine (BD Biosciences), according to the manufacturer's instructions. The tissue homogenates were filtered using a 30 μm cell strainer (BD Biosciences). The leukocytes composition of tumor-draining lymph nodes (LNs), axial and brachial LNs from healthy control mice were determined by dissociation, cell counting and immunostaining. The viability of the leukocytes was evaluated by Trypan blue exclusion, and these cells were used for cell activation and immunolabeling assays.
Antibodies and flow cytometry analysis
For immunostaining, PerCP-, PE-and fluorescein isothiocyanate-conjugated antibodies (Abs) against CD3 (17A2), CD4 (H129.19), CD8 (RPA-T8 and HIT8a), CD19 (1D3), PD-1 (J43), PD-L1 (MIH5), PD-L2 (TY25), DC (33D1) and F4/80 (BM8), and the respective goat and rat isotype controls were used (BD Biosciences). Samples were run on a FACSort flow cytometer, and the data was analyzed using CellQuest software (BD Biosciences).
Histological analysis
Tissue samples were collected from tumor sites and fixed with 10% (vol/vol) formalin for 6 h at room temperature. The tissues were subsequently dehydrated in ethyl alcohol, followed by washes in xylol, and were embedded in paraffin. Each sample was sectioned into slices 4-7 μm thick that were dried onto slides and stained with hematoxylin and eosin. Slides were examined in a blinded fashion by a pathologist and classified as papillomas or carcinoma. Carcinoma specimens were graded as well, moderately or poorly differentiated.
Immunohistochemistry
A Vector Kit (Vectastain Elite ABC kit, Vector Labs, Burlingame, CA) was used for immunohistochemical analysis of all markers. In brief, 4 μm tissue sections were cut, and slides were baked in a 58°C oven overnight. Sections were deparaffinized in xylene (Fisher Scientific, Pittsburgh, PA) for 15 min, washed twice in ethanol, and endogenous peroxidase activity was blocked with 3% H 2 O 2 -methanol for 30 min. Sections were incubated with Molico® milk powder for 20 min to block non-specific Ab binding sites. Sections were then incubated with the following primary Abs: CK1 (GeneTex, San Antonio, TX), filaggrin (Covance, Princeton, NJ), loricrin (Covance), CK5 and 8 (Chemicon, Temecula, CA) and proliferating cell nuclear antigen (PCNA) (Millipore, Billerica, MA). Sections were incubated with a primary Ab overnight at 4°C, followed by incubations with peroxidase-labeled anti-rabbit or mouse IgG for 30 min. Staining was completed with a 10 min incubation with the substrate-chromogen solution. The sections were counterstained with 0.1% hematoxylin. Appropriate positive and negative control samples were used. Tissue staining was quantified using image analysis software (LEICA LAS Image Analysis; LEICA Microsystems, Wetzlar, Germany).
Cytokine assays
Interleukin-10, TGF-β and IFN-γ levels were quantified by enzyme-linked immunosorbent assay, according to the manufacturer's instructions (BD Biosciences), as described previously (37) . The concentrations of each cytokine were dosed as pg/ml, and the results were normalized and expressed as mg per protein.
Statistical analysis
The results are expressed as the mean ± SD or mean ± standard error of the mean and statistical analysis was performed using analysis of variance to compare multiple groups or by the parametric Student's t-test for the comparison of two groups (GraphPad software 4). Log-rank (Mantel-Cox) test was used to determine whether the anti-PD-1-treated mice had better outcomes than the wild-type mice. Values of P < 0.05 were considered statistically significant. Figure 1C ). These findings support our hypothesis that PD-1/PD-L1 activation is involved in the regulation of immune response during SCC.
Results
Characterization of PD-1 + cells in tumor of mice with SCC
Effect of PD-1 inhibition on the SCC development in mice
Next, we assessed the role of PD-1 + cells during the development of SCC by immune neutralization of PD-1 molecules. The mice were followed for 20 weeks and we did not observe any difference in the mortality between both groups (data not shown). The number and rate of appearance (tumor incidence and initiation rate) of papillomas were delayed in anti-PD-1-treated mice (Figure 2A ). Papillomas were found in 100% of IgG-treated mice 10 weeks after carcinogenic induction, whereas papillomas were found after 12 weeks in anti-PD-1-treated mice (Figure 2A) . Moreover, the papilloma average number was lower in anti-PD-1-treated mice when compared with IgG-treated mice ( Figure 2B) . These results were confirmed by macroscopic analysis that demonstrated treatment with anti-PD-1 delayed the carcinogenic process because the number and rate of appearance of papillomas were significantly lower in anti-PD-1-treated mice ( Figure 2C and D) . Histological analysis revealed a pronounced presence of inflammatory infiltrates and a lack of epithelial islet formation in anti-PD-1-treated mice compared with control groups (non-tumorigenic control mice and IgG-treated mice) ( Figure 3A-C) . Tumor differentiation was assessed to determinate the effects of PD-1 blockage in tumor grade. The results show that 75% (9/12) anti-PD-1-treated mice developed benign tumors (papilloma), 8% (1/12) poorly differentiated SCC and 17% (2/12) well-differentiated SCC (Table I ). In contrast, 83% (10/12) IgG-treated mice developed well-differentiated SCC and only 17% papilloma (Table I) . Additionally, anti-PD-1-treated mice showed a lower degree of tumor invasiveness with smaller areas of tumor involvement over the same time course ( Figure 3B) . Thus, our results indicate that the presence of PD-1 + cells affected skin tumor initiation and development.
Since the alterations of CKs expression are closely associated with the development of SCC, we analyzed the effects of PD-1 blockage on the expression of CKs in tumor sites and normal skin ( Figure 3D , G, J, M and P). Positive immunostaining for CK1, loricrin, filaggrin, CK5-8 and PCNA were observed in the normal skin (non-tumorigenic control mice). The expression of CK1, loricrin and filaggrin was higher in anti-PD-1-treated mice ( Figure 3D , G and J) when compared with samples from IgG-treated mice ( Figure 3F , I and L). Low expression of CK5-8 was observed in SCC lesions from anti-PD-1-treated mice ( Figure 3N ), in contrast to the higher expression of CK5-8 in SCC lesions from IgGtreated mice ( Figure 3O ). No significant differences in PCNA expression was observed between the groups. It has been demonstrated that CK5 + and CD8 + PD-1 + lymphocytes in skin was determined using flow cytometry. (C) F4/80 + macrophages were gated and coexpression of PD-L1 and PD-L2 in the skin was determined. Data from three independent experiments with eight mice per group. *P < 0.05.
PD-1 in the squamous cell carcinoma
and CK8 are overexpressed in various cancer cells including human breast carcinoma, lung SCC and gastric adenocarcinoma (40) (41) (42) (43) (44) (45) . These results suggesting that the absence of PD-1 activation impairs the progression to SCC, which is correlated with the expression of specific CKs.
Effect of PD-1 inhibition on the antitumor immune response
The most conclusive readout that allows measurement of the in vivo relevance of signaling by PD-1 is the antitumor immune response characterized by lower numbers of papillomas, delay in the development of SCC, intense inflammatory infiltrates and a differential expression of CKs in tumor lesions. We therefore investigated the inflammatory infiltrate and the profile of cytokines in the tumor microenvironment 16 weeks after carcinogenesis. Our results showed that 12 ± 3.9 × 10 6 leukocytes were present in the tumor samples ( Figure 4A ) of anti-PD-1-treated mice and 8 ± 0.3 × 10 5 in the tumor samples of IgG-treated mice ( Figure 4A ). Of these leukocytes, 54 ± 11.7% represented T cells (CD3 + ) in the tumor samples from anti-PD-1-treated mice ( Figure 4B ). Of these T cells, 40 ± 10.1% were CD4 + and 14 ± 2.2% were CD8 + ( Figure 4C ). IgG-treated mice had a significantly lower percentage of CD3 + T cells (34.9 ± 10.4%) infiltrating tumor lesions, and significantly lower percentages of CD4 + and CD8 + T cells infiltrating tumor lesions, compared with anti-PD-1-treated mice ( Figure 4C ). We found that anti-PD-1-treated mice had a higher percentage of B cells (CD19 + ) (15.3 ± 4.6%) infiltrating tumor samples than the control group (3.6 ± 1.5%) ( Figure 4C ). Interestingly, DCs (30.1 ± 1.2%) and macrophages (86.7 ± 1.1%) were found infiltrating tumor samples at higher number from IgG-treated mice than from anti-PD-1-treated mice ( Figure 4C ). In addition, the blockage of PD-1 significantly decreased the percentage of CD4 + PD-1 + T cells and in SCC lesions ( Figure 4B) .
We then analyzed the phenotype of the leukocyte subpopulations in the LNs from anti-PD-1-treated mice and control groups ( Figure 4D ). We found that the frequencies of CD3 + T cells in anti-PD-1-treated mice were similar to those detected in IgG-treated mice ( Figure 4D ). We also analyzed the population of macrophages and found significant differences between the anti-PD-1-treated mice (38 ± 8.8%) and IgG-treated mice (75.9 ± 15%) ( Figure 4D ). Similarly to macrophages, DCs (CD11c + CD11b + ) were increased in the LNs from IgG-treated mice (13.6 ± 0.1%) when compared with anti-PD-1-treated mice (1.16 ± 0.03%) ( Figure 4D ). These data indicate that PD-1 blockage improved the accumulation of CD4 + and CD8 + T cells and B cells on tumor lesions, which could be associated with better antitumor immune responses.
Based on these observations, we next analyzed how PD-1 activation regulated the levels of cytokines during SCC. For this, we quantified the levels of interleukin-10, TGF-β and IFN-γ in tumor samples and LNs from anti-PD-1-treated mice and control IgG-treated mice ( Figure 5A and B). Our data showed that samples from anti-PD-1-treated mice contained significantly elevated levels of IFN-γ when compared with samples from IgG-treated mice ( Figure 5A ). Conversely, we found lower levels of TGF-β in lesions and LNs from anti-PD-1-treated mice when compared with IgG-treated mice ( Figure 5A and B) . These data suggest that blockage of PD-1 could result in a predominantly Th1 tumor environment increasing IFN-γ and decreasing TGF-β, which is crucial for the protective antitumor responses.
Discussion
The PD-1/PD-L1 pathway is an important inhibitory pathway in the tumor microenvironment (7). PD-1 expression on tumor-infiltrating CD8 + T cells and increased expression of PD-L1 on tumor cells correlates with poor prognosis in patients with different types of cancers, including breast, ovarian, pancreatic, gastric, kidney and bladder cancers (46) . In the present study, we found that PD-1-PD-L1 activation contributes to the SCC development revealed by increased numbers of papillomas per mouse followed by a differential expression of CKs, and a direct effect on the regulation of antitumor immune responses.
In SCC, the PD-1/PD-L1 pathway seems to be an important immunosuppression mechanism. For example, Malaspina et al. (27) found that the expression of PD-L1 was intense in oral SCC and moderate in is consistent with the hypothesis that the blockade of PD-1 leads to a more effective antitumor immune response. Macrophages are recognized for having the potential not only to elicit tumor and tissue destructive reactions but also to promote tumor progression and metastasis (49) (50) (51) . The decreased frequency of macrophage cells in the tumor microenvironment could be a direct consequence of the control of tumor development observed in anti-PD-1-treated mice. It is largely known that the binding of PD-1 with their ligands (PD-L1 and PD-L2) induces the apoptosis of immune cells (52) . Thus, the high rate of apoptotic cells observed in the microenvironment may be related to macrophage infiltration in tumor (53) , contributing to the modulation of the local immune response. In addition, PD-1 expression has recently been identified on DCs, where it suppresses innate immunity against infectious disease (54) . A recent study shows that DCs in the ovarian tumor microenvironment express both PD-1 and PD-L1 and use the PD-L1/PD-1 inhibitory pathway in mediating immune suppression (46) . Thus, the presence of PD-1 cells in the tumor microenvironment in general may regulate the local immune response, leading to tumor growth by inhibiting CD8 + T cells, enhancing both macrophage and DC number in the tumor site in SCCs. In accordance, we have observed an increasing in the intratumoral CD8 + T lymphocytes when mice were treated with anti-PD-1 Abs.
Since the histological and cytogenetic abnormalities that occur during mouse skin carcinogenesis have been associated with changes in the expression patterns of select CK genes (55), another important finding of the present manuscript is the characterization of CK expression during SCC with and without blocking PD-1. Loss of CK1, loricrin and filaggrin expression combined with an accompanying increased CK5-8 and PCNA expression are characteristic patterns observed during the progression of papillomas to SCC (53) (54) (55) (56) (57) . These alterations have been confirmed in our study during SCC development. The treatment with anti-PD-1 interfered with SCC development coincident with the increased expression of CK1, loricrin, filaggrin but not CK5-8 and PCNA. Thus, the results reported here indicate that PD-1 + cells depletion prevented malignant conversion of papillomas to SCC.
Higher levels of IFN-γ and lower levels of TGF-β in the tumor microenvironment from anti-PD-1-treated mice might provide an explanation for the control of tumor development. IFN-γ not only activates effector cells including CD8 + T cells and natural killer cells, but also orchestrates responses in tumors that facilitate their escape from immune attack and inhibit angiogenesis within the tumor (58) . In the other hand, TGF-β signaling is known to function as a tumor promoter (59) . In human cancer, the overexpression of TGF-β correlates with tumor progression, metastasis, angiogenesis and poor prognostic outcome (60, 61) . In addition, the expression of TGF-β correlates with an increase in the conversion frequency from papilloma to SCC at later stages of skin carcinogenesis (62) . Collectively, our findings suggest that PD-1 activation is closely linked to SCC, thereby providing potential new therapeutic strategies for this malignancy. 
